• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab.

作者信息

Khunger Monica, Velcheti Vamsidhar

机构信息

Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio.

Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio.

出版信息

J Thorac Oncol. 2017 Jul;12(7):e96-e97. doi: 10.1016/j.jtho.2017.03.008.

DOI:10.1016/j.jtho.2017.03.008
PMID:28629548
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7128997/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9a2/7128997/73c9992a9e52/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9a2/7128997/73c9992a9e52/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9a2/7128997/73c9992a9e52/gr1_lrg.jpg

相似文献

1
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab.1例特发性肺纤维化合并肺鳞状细胞癌患者接受纳武单抗治疗的病例
J Thorac Oncol. 2017 Jul;12(7):e96-e97. doi: 10.1016/j.jtho.2017.03.008.
2
Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis.尼伏单抗治疗特发性肺纤维化肺腺癌患者获得持久缓解。
Thorac Cancer. 2018 Nov;9(11):1519-1521. doi: 10.1111/1759-7714.12853. Epub 2018 Aug 28.
3
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer.纳武单抗在一名原发性肺癌患者中的远隔效应
J Thorac Oncol. 2017 Sep;12(9):e143-e144. doi: 10.1016/j.jtho.2017.05.004.
4
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.肝转移与接受纳武利尤单抗治疗的非小细胞肺癌患者的无进展生存期较差相关。
J Thorac Oncol. 2017 Sep;12(9):e140-e141. doi: 10.1016/j.jtho.2017.04.027.
5
Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.一名鳞状细胞肺癌患者使用纳武利尤单抗后出现中枢神经系统假性进展，随后出现长期缓解。
J Thorac Oncol. 2018 Sep;13(9):e183-e184. doi: 10.1016/j.jtho.2018.05.001.
6
[Can nivolumab be used safely in idiopathic pulmonary fibrosis?].[纳武单抗能否安全用于特发性肺纤维化？]
Rev Mal Respir. 2019 Feb;36(2):209-213. doi: 10.1016/j.rmr.2018.11.001. Epub 2019 Jan 24.
7
Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab.纳武单抗治疗转移性肺鳞状细胞癌患者后发生获得性血友病A，使用利妥昔单抗成功治疗。
Clin Lung Cancer. 2019 Sep;20(5):e560-e563. doi: 10.1016/j.cllc.2019.06.022. Epub 2019 Jun 26.
8
[A Case of Myocardial and Cutaneous Metastases of Squamous Cell Lung Cancer Post Left Pneumonectomy and Radical Surgery for Cutaneous Metastasis during Nivolumab Therapy].[1例肺鳞状细胞癌左肺切除术后发生心肌和皮肤转移及在纳武单抗治疗期间行皮肤转移灶根治性手术的病例]
Gan To Kagaku Ryoho. 2018 Oct;45(10):1441-1444.
9
Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.纳武利尤单抗治疗 4 周后的中性粒细胞与淋巴细胞比值可作为预处理非小细胞肺癌患者的预测标志物。
Thorac Cancer. 2018 Oct;9(10):1291-1299. doi: 10.1111/1759-7714.12838. Epub 2018 Aug 20.
10
Nivolumab improves survival for patients with advanced lung cancer.纳武单抗可提高晚期肺癌患者的生存率。
Cancer. 2017 Sep 1;123(17):3211. doi: 10.1002/cncr.30930.

引用本文的文献

1
Risk factors and management of lung cancer in idiopathic pulmonary fibrosis: A comprehensive review.特发性肺纤维化中肺癌的危险因素与管理：一项综述
Sarcoidosis Vasc Diffuse Lung Dis. 2025 Mar 18;42(1):15604. doi: 10.36141/svdld.v42i1.15604.
2
Lung Cancer and Interstitial Lung Diseases.肺癌与间质性肺疾病
Cancers (Basel). 2024 Aug 13;16(16):2837. doi: 10.3390/cancers16162837.
3
[Research Progress on Pathogenic Mechanism and Potential Therapeutic Drugs of 
Idiopathic Pulmonary Fibrosis Complicated with Non-small Cell Lung Cancer].

本文引用的文献

1
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.接受抗程序性死亡蛋白1/程序性死亡配体1治疗的患者发生的肺炎
J Clin Oncol. 2017 Mar;35(7):709-717. doi: 10.1200/JCO.2016.68.2005. Epub 2016 Sep 30.
2
Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.分子途径：免疫检查点抗体及其毒性。
Clin Cancer Res. 2016 Sep 15;22(18):4550-5. doi: 10.1158/1078-0432.CCR-15-2569. Epub 2016 Jul 19.
3
Idiopathic pulmonary fibrosis and lung cancer: a clinical and pathogenesis update.
[特发性肺纤维化合并非小细胞肺癌的发病机制及潜在治疗药物的研究进展]
Zhongguo Fei Ai Za Zhi. 2022 Oct 20;25(10):756-763. doi: 10.3779/j.issn.1009-3419.2022.101.45. Epub 2022 Sep 28.
4
The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review.特发性肺纤维化的致癌格局：一项叙述性综述。
Transl Lung Cancer Res. 2022 Mar;11(3):472-496. doi: 10.21037/tlcr-21-880.
5
Case of Merkel cell carcinoma in a patient with pre-existing ILD.患者原有间质性肺病的 Merkel 细胞癌病例。
J Immunother Cancer. 2020 Nov;8(2). doi: 10.1136/jitc-2020-001672.
6
Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity.成纤维细胞中 JUN 的激活促进了促纤维化程序，并调节了保护性免疫。
Nat Commun. 2020 Jun 3;11(1):2795. doi: 10.1038/s41467-020-16466-4.
7
[A Review of Drug Therapy of Lung Cancer with Interstitial Lung Disease].[间质性肺疾病合并肺癌的药物治疗综述]
Zhongguo Fei Ai Za Zhi. 2020 Apr 20;23(4):286-293. doi: 10.3779/j.issn.1009-3419.2020.102.01.
8
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer.免疫检查点抑制剂在非小细胞肺癌患者中的肺部并发症。
Eur Respir Rev. 2019 Oct 9;28(153). doi: 10.1183/16000617.0058-2019. Print 2019 Sep 30.
9
Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?免疫检查点能否成为治疗特发性肺纤维化的有效靶点？
J Clin Med. 2019 Sep 26;8(10):1547. doi: 10.3390/jcm8101547.
10
Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study.特发性肺纤维化中膜性程序性死亡配体1表达及可溶性程序性死亡配体1血浆水平——一项初步研究
J Thorac Dis. 2018 Dec;10(12):6660-6669. doi: 10.21037/jtd.2018.11.16.
特发性肺纤维化与肺癌：临床与发病机制的最新进展
Curr Opin Pulm Med. 2015 Nov;21(6):626-33. doi: 10.1097/MCP.0000000000000217.
4
Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity.程序性死亡-1通路的阻断可恢复结节病CD4(+) T细胞的增殖能力。
Am J Respir Crit Care Med. 2014 Sep 1;190(5):560-71. doi: 10.1164/rccm.201401-0188OC.
5
Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study.肺癌与隐源性纤维性肺泡炎。一项基于人群的队列研究。
Am J Respir Crit Care Med. 2000 Jan;161(1):5-8. doi: 10.1164/ajrccm.161.1.9906062.